Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28597862 | 0.86 | LPAR3 (0.39) | — | |
| SCHEMBL28597772 | 0.85 | MVD (0.39) | — | |
| SCHEMBL17036886 | 0.81 | — | — | |
| SCHEMBL14566357 | 0.79 | HDAC3 (0.35) | — | |
| SCHEMBL23378043 | 0.76 | CA14 (0.31) | — | |
| SCHEMBL23408572 | 0.74 | — | — | |
| SCHEMBL14086322 | 0.73 | CA12 (0.40) | PKM | |
| SCHEMBL17613643 | 0.72 | — | — | |
| SCHEMBL16575564 | 0.72 | — | — | |
| SCHEMBL2170469 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-05-27 | — | — | US | disclosed |
| US-20210147456-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295202-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | PKM 4228/4885 |
| US-20210147456-A1 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, SLC29A1 | PKM 4228/4885 |
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, NOX1 | PKM 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.